Document is current
Any future updates will be listed below
-
Authors
In, Gino K
Chandra, Sunandana
Sosman, Jeffrey
Barrett, Erin
Wysong, Ashley
Marr, Alissa
Mammen, Joshua
Thomas, Jacob
Won, Thomas
Sandin, Anisa
Marmolejo, Sophia
Zeng, Andrew
Ito, Fumito
Kokot, Niels
Swanson, Mark
Kwon, Daniel
Tsao-Wei, Denice
Groshen, Susan
Kelly, Kevin
Martinez, Hugo Lara
Sherrod, Andy
Declerck, Brittney
Kim, Gene
Peng, David
Hu, Jenny C
-
Clinical Trials BETA
Clinical trials referenced in this document:
nct04315701 at ClinicalTrials.govDocuments that mention this clinical trial
774 NeoPOWER: A phase II study of neoadjuvant PD-1 blockade with cemiplimab in high risk localized, locally recurrent and regionally advanced cutaneous squamous cell carcinoma
https://doi.org/10.1136/jitc-2023-sitc2023.0774
524 Primary analysis of patients with high-risk localized, locally recurrent, or regionally advanced cutaneous squamous cell carcinoma (CSCC) treated with neoadjuvant PD-1 therapy (NeoPOWER)
https://doi.org/10.1136/jitc-2025-sitc2025.0524
- License Information
